Creative Planning Purchases Shares of 16,466 Regulus Therapeutics Inc. (NASDAQ:RGLS)

Creative Planning purchased a new stake in Regulus Therapeutics Inc. (NASDAQ:RGLS) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 16,466 shares of the biopharmaceutical company’s stock, valued at approximately $26,000.

A number of other institutional investors have also recently bought and sold shares of the stock. Vanguard Group Inc. lifted its position in shares of Regulus Therapeutics by 158.4% in the first quarter. Vanguard Group Inc. now owns 740,215 shares of the biopharmaceutical company’s stock worth $2,132,000 after purchasing an additional 453,784 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Regulus Therapeutics by 56.4% in the second quarter. Renaissance Technologies LLC now owns 118,100 shares of the biopharmaceutical company’s stock worth $211,000 after purchasing an additional 42,600 shares in the last quarter. Rhumbline Advisers bought a new stake in shares of Regulus Therapeutics in the second quarter worth $136,000. SG Americas Securities LLC bought a new stake in shares of Regulus Therapeutics in the third quarter worth $33,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Regulus Therapeutics in the second quarter worth $352,000. Institutional investors own 92.38% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. StockNews.com raised shares of Regulus Therapeutics to a “sell” rating in a research report on Tuesday, September 17th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Regulus Therapeutics in a research report on Monday. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $7.00 price target on shares of Regulus Therapeutics in a research report on Wednesday, August 14th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $10.80.

Regulus Therapeutics Price Performance

NASDAQ:RGLS opened at $1.50 on Thursday. Regulus Therapeutics Inc. has a one year low of $1.08 and a one year high of $3.79. The company has a market cap of $98.25 million, a P/E ratio of -1.40 and a beta of 1.63. The firm’s fifty day moving average price is $1.55 and its two-hundred day moving average price is $1.81.

Regulus Therapeutics (NASDAQ:RGLS) last released its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.03). As a group, equities research analysts expect that Regulus Therapeutics Inc. will post -0.83 earnings per share for the current year.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.